{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 64,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "other",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/18",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.5,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Dual-axis line chart showing HBI0101/mL Blood and dFLC (mg/L) over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6eee87c6-ef43-4e2a-87e7-5222f06c79d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*dFLC (=involved FLC-uninvolved FLC)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ac7a129-5f67-48dd-a69c-84686956ae0e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: NXC-201 (formerly known as HBI0101). ImmixBio ASGCT Presentation Los Angeles 2023. E. Lebel et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2fec698-347a-4117-842b-2786df066086",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "N-GENIUS Technology Platform – NXC-201 rapidly eliminates diseased AL Amyloidosis plasma cells and exits within ~ 30 days (2/2)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ecfc776d-e4d8-4ebe-bdbe-4219229b81c0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 18,
      "from": 9,
      "beatId": "557afc5a-25a6-4b91-ae35-178f52e60ac2",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 9-18 present the N-GENIUS Platform, NXC-201 MoA, and its advantages",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}